Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...
This Magnificent Dividend Stock Is as Healthy as It Gets
Johnson & Johnson has been a stalwart dividend stock over the years because it has maintained a healthy financial profile, ...
Johnson & Johnson (NYSE:JNJ) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...
Becker's Spine Review12h
8 medtech notes: Aurora Spine, SI-Bone and more
Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the ...
Johnson & Johnson’s Growth Potential Highlighted by Strong Q3 Earnings and Promising Pipeline
David Risinger, an analyst from Leerink Partners, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The ...
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.
BioSpace7h
J&J Scraps Pipeline Assets Including Alzheimer’s and Parkinson’s Candidates
Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back from the infectious diseases market.
Merck KGaA Cuts Medium-Term Healthcare, Life-Science Outlook but Lifts Electronics Guidance
Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent pipeline setbacks but raised its electronics forecast, citing strong ...